GLAXOSMITHKLINE PHARMA LT

During the Q1 FY 2027 earnings call, management reported a strong performance with sales reaching INR 924 crores, reflecting a 15% year-on-year growth. EBITDA grew by 17%, and profit after tax increased by 24%, driven by a balanced growth across various therapy areas, including anti-infectives and vaccines. Management highlighted the importance of their innovation portfolio, which contributed approximately 7% to total revenues. The call emphasized the company's focus on three priorities: relentless top-line growth, accelerating the pipeline of innovative assets, and simplifying processes to enhance efficiency. Management noted that the overall industry grew by 13.5%, with GSK outperforming the market. They also discussed the successful launch of products like Shingrix and the positive reception of their oncology portfolio. The management expressed confidence in sustaining growth momentum while managing operational expenses effectively.

Management emphasized strong growth and successful product launches.